Bioventus Inc. (NASDAQ: BVS) Stock Competitors & Peer Comparison
See BVS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BVS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BVS | $14.23 | -0.97% | 972.9M | 18.89 | $0.76 | N/A |
| ABT | $108.99 | -1.34% | 188.2B | 20.88 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.38 | +2.39% | 119.2B | 16.84 | $5.53 | +3.08% |
| SYK | $304.31 | -2.52% | 118.1B | 23.00 | $13.39 | +1.13% |
| BSX | $48.01 | -0.74% | 69.8B | 15.15 | $3.10 | N/A |
| EW | $90.06 | -0.84% | 51.7B | 33.25 | $2.70 | N/A |
| DXCM | $88.04 | -1.84% | 33.9B | 35.18 | $2.55 | N/A |
| GEHC | $68.94 | -2.30% | 31.5B | 15.29 | $4.56 | +0.20% |
| PHG | $25.93 | -1.67% | 25.5B | 14.88 | $1.75 | +3.80% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BVS vs ABT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ABT has a market cap of 188.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ABT trades at $108.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ABT's P/E ratio is 20.88. In terms of profitability, BVS's ROE is +0.28%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BVS is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BVS vs BSX-PA Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BVS's ROE is +0.28%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BVS is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
BVS vs MDT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, MDT has a market cap of 119.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while MDT trades at $94.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas MDT's P/E ratio is 16.84. In terms of profitability, BVS's ROE is +0.28%, compared to MDT's ROE of +0.14%. Regarding short-term risk, BVS is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
BVS vs SYK Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SYK has a market cap of 118.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SYK trades at $304.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SYK's P/E ratio is 23.00. In terms of profitability, BVS's ROE is +0.28%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BVS is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
BVS vs BSX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BSX has a market cap of 69.8B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BSX trades at $48.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BSX's P/E ratio is 15.15. In terms of profitability, BVS's ROE is +0.28%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BVS is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BVS vs EW Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while EW trades at $90.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas EW's P/E ratio is 33.25. In terms of profitability, BVS's ROE is +0.28%, compared to EW's ROE of +0.10%. Regarding short-term risk, BVS is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BVS.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BVS vs DXCM Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, DXCM has a market cap of 33.9B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while DXCM trades at $88.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas DXCM's P/E ratio is 35.18. In terms of profitability, BVS's ROE is +0.28%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BVS is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for BVS.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BVS vs GEHC Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while GEHC trades at $68.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas GEHC's P/E ratio is 15.29. In terms of profitability, BVS's ROE is +0.28%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, BVS is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for BVS.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BVS vs PHG Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PHG trades at $25.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PHG's P/E ratio is 14.88. In terms of profitability, BVS's ROE is +0.28%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BVS is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BVS.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BVS vs ZBH Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ZBH trades at $98.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ZBH's P/E ratio is 11.67. In terms of profitability, BVS's ROE is +0.28%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BVS is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BVS vs ABMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BVS's ROE is +0.28%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BVS is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BVS vs PEN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PEN trades at $322.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PEN's P/E ratio is 83.90. In terms of profitability, BVS's ROE is +0.28%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BVS is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BVS vs SWAV Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BVS's ROE is +0.28%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BVS is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
BVS vs SNN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SNN trades at $28.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SNN's P/E ratio is 13.50. In terms of profitability, BVS's ROE is +0.28%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BVS is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BVS vs ALGN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ALGN trades at $158.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ALGN's P/E ratio is 14.57. In terms of profitability, BVS's ROE is +0.28%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BVS is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
BVS vs GKOS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while GKOS trades at $178.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas GKOS's P/E ratio is -209.80. In terms of profitability, BVS's ROE is +0.28%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BVS is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check GKOS's competition here
Globus Medical, Inc. (NYSE: GMED)
BVS vs GMED Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while GMED trades at $78.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas GMED's P/E ratio is 17.59. In terms of profitability, BVS's ROE is +0.28%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BVS is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BVS.Check GMED's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BVS vs BIO Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BIO trades at $385.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BIO's P/E ratio is 41.79. In terms of profitability, BVS's ROE is +0.28%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BVS is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BVS vs BIO-B Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, BVS's ROE is +0.28%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BVS is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
BVS vs PODD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PODD trades at $146.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PODD's P/E ratio is 25.65. In terms of profitability, BVS's ROE is +0.28%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BVS is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
BVS vs MASI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas MASI's P/E ratio is 44.43. In terms of profitability, BVS's ROE is +0.28%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BVS is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BVS.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BVS vs BRKR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BRKR trades at $58.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BRKR's P/E ratio is 29.85. In terms of profitability, BVS's ROE is +0.28%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BVS is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
BVS vs BRKRP Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BRKRP trades at $432.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BRKRP's P/E ratio is 238.04. In terms of profitability, BVS's ROE is +0.28%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, BVS is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BVS vs NARI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NARI's P/E ratio is -59.24. In terms of profitability, BVS's ROE is +0.28%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BVS is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
BVS vs HAE Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while HAE trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas HAE's P/E ratio is 20.52. In terms of profitability, BVS's ROE is +0.28%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BVS is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for BVS.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
BVS vs LIVN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while LIVN trades at $82.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas LIVN's P/E ratio is 19.29. In terms of profitability, BVS's ROE is +0.28%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BVS is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BVS vs ITGR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ITGR trades at $126.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ITGR's P/E ratio is 19.76. In terms of profitability, BVS's ROE is +0.28%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BVS is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BVS vs IRTC Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while IRTC trades at $122.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas IRTC's P/E ratio is -287.05. In terms of profitability, BVS's ROE is +0.28%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BVS is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for BVS.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
BVS vs AXNX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BVS's ROE is +0.28%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BVS vs TMDX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while TMDX trades at $88.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas TMDX's P/E ratio is 44.15. In terms of profitability, BVS's ROE is +0.28%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BVS is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
BVS vs NEOG Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NEOG trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NEOG's P/E ratio is 41.57. In terms of profitability, BVS's ROE is +0.28%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, BVS is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BVS.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BVS vs AXGN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AXGN trades at $48.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AXGN's P/E ratio is 123.95. In terms of profitability, BVS's ROE is +0.28%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BVS is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BVS vs UFPT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while UFPT trades at $287.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas UFPT's P/E ratio is 29.27. In terms of profitability, BVS's ROE is +0.28%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BVS is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BVS vs ESTA Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ESTA trades at $74.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ESTA's P/E ratio is -57.38. In terms of profitability, BVS's ROE is +0.28%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BVS is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BVS vs NUVA Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BVS's ROE is +0.28%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BVS is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BVS vs NVCR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NVCR trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NVCR's P/E ratio is -13.57. In terms of profitability, BVS's ROE is +0.28%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BVS is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BVS vs BFLY Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BFLY trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BFLY's P/E ratio is -30.35. In terms of profitability, BVS's ROE is +0.28%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BVS is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BVS vs INSP Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while INSP trades at $63.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas INSP's P/E ratio is 27.34. In terms of profitability, BVS's ROE is +0.28%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BVS is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BVS.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
BVS vs CNMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CNMD trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CNMD's P/E ratio is 10.84. In terms of profitability, BVS's ROE is +0.28%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BVS is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BVS vs ATEC Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ATEC trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ATEC's P/E ratio is -155.50. In terms of profitability, BVS's ROE is +0.28%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BVS is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BVS vs TNDM Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while TNDM trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas TNDM's P/E ratio is -21.97. In terms of profitability, BVS's ROE is +0.28%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BVS is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
BVS vs HSKA Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BVS's ROE is +0.28%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BVS is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BVS.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BVS vs IART Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while IART trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas IART's P/E ratio is 6.97. In terms of profitability, BVS's ROE is +0.28%, compared to IART's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for BVS.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
BVS vs AORT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AORT trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AORT's P/E ratio is 42.67. In terms of profitability, BVS's ROE is +0.28%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BVS vs PRCT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PRCT trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PRCT's P/E ratio is -11.02. In terms of profitability, BVS's ROE is +0.28%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BVS is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BVS vs AVNS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BVS's ROE is +0.28%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BVS is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BVS.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BVS vs LMRI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while LMRI trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas LMRI's P/E ratio is -23.15. In terms of profitability, BVS's ROE is +0.28%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BVS is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BVS vs SILK Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SILK's P/E ratio is -18.96. In terms of profitability, BVS's ROE is +0.28%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BVS is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SILK's competition here
Enovis Corporation (NYSE: ENOV)
BVS vs ENOV Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ENOV trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ENOV's P/E ratio is 5.55. In terms of profitability, BVS's ROE is +0.28%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BVS is similarly volatile compared to ENOV. This indicates similar risk in terms of short-term price fluctuations for BVS.Check ENOV's competition here
IRadimed Corporation (NASDAQ: IRMD)
BVS vs IRMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while IRMD trades at $84.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas IRMD's P/E ratio is 43.51. In terms of profitability, BVS's ROE is +0.28%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BVS is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
BVS vs FNA Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas FNA's P/E ratio is -19.83. In terms of profitability, BVS's ROE is +0.28%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BVS is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BVS.Check FNA's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BVS vs CBLL Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CBLL has a market cap of 932.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CBLL trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CBLL's P/E ratio is -13.96. In terms of profitability, BVS's ROE is +0.28%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BVS is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BVS vs BBNX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BBNX has a market cap of 896.2M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BBNX trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BBNX's P/E ratio is -12.07. In terms of profitability, BVS's ROE is +0.28%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BVS is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BBNX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BVS vs AHCO Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AHCO has a market cap of 873.5M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AHCO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AHCO's P/E ratio is 13.10. In terms of profitability, BVS's ROE is +0.28%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BVS is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
BVS vs INMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, INMD has a market cap of 853M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while INMD trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas INMD's P/E ratio is 10.31. In terms of profitability, BVS's ROE is +0.28%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BVS is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BVS vs AVR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, AVR has a market cap of 847.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while AVR trades at $9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas AVR's P/E ratio is -4.49. In terms of profitability, BVS's ROE is +0.28%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BVS is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BVS vs CSII Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CSII's P/E ratio is -20.83. In terms of profitability, BVS's ROE is +0.28%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BVS is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BVS vs SIBN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SIBN has a market cap of 826.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SIBN trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SIBN's P/E ratio is -54.82. In terms of profitability, BVS's ROE is +0.28%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BVS is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BVS vs VREX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, VREX has a market cap of 779.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas VREX's P/E ratio is 19.49. In terms of profitability, BVS's ROE is +0.28%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BVS is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BVS vs SSII Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SSII has a market cap of 678.4M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SSII trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SSII's P/E ratio is -66.12. In terms of profitability, BVS's ROE is +0.28%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BVS is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BVS vs SRDX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BVS's ROE is +0.28%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BVS is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BVS vs CTKB Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CTKB trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CTKB's P/E ratio is -24.90. In terms of profitability, BVS's ROE is +0.28%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BVS is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BVS vs KIDS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, KIDS has a market cap of 580.2M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while KIDS trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas KIDS's P/E ratio is -19.14. In terms of profitability, BVS's ROE is +0.28%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BVS is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BVS vs APEN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas APEN's P/E ratio is -9.43. In terms of profitability, BVS's ROE is +0.28%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BVS is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BVS vs DCTH Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while DCTH trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, BVS's ROE is +0.28%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BVS is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for BVS.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BVS vs ZIMV Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BVS's ROE is +0.28%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
BVS vs CERS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CERS has a market cap of 517.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CERS trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CERS's P/E ratio is -51.30. In terms of profitability, BVS's ROE is +0.28%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BVS is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BVS vs NPCE Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NPCE has a market cap of 502.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NPCE trades at $14.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NPCE's P/E ratio is -25.88. In terms of profitability, BVS's ROE is +0.28%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BVS is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BVS vs TCMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, TCMD has a market cap of 496.5M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while TCMD trades at $21.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas TCMD's P/E ratio is 20.38. In terms of profitability, BVS's ROE is +0.28%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BVS is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BVS vs SGHT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SGHT has a market cap of 456M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SGHT trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SGHT's P/E ratio is -14.96. In terms of profitability, BVS's ROE is +0.28%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BVS is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BVS vs CARL Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CARL has a market cap of 421.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CARL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CARL's P/E ratio is -10.85. In terms of profitability, BVS's ROE is +0.28%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BVS is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CARL's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BVS vs CLPT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CLPT has a market cap of 421.4M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CLPT trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CLPT's P/E ratio is -11.91. In terms of profitability, BVS's ROE is +0.28%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BVS is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BVS vs SENS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SENS has a market cap of 413.8M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SENS trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SENS's P/E ratio is -4.44. In terms of profitability, BVS's ROE is +0.28%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BVS is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SENS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BVS vs PACB Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PACB has a market cap of 403.8M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PACB trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PACB's P/E ratio is -3.17. In terms of profitability, BVS's ROE is +0.28%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BVS is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BVS vs OFIX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, OFIX has a market cap of 376.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while OFIX trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas OFIX's P/E ratio is -6.06. In terms of profitability, BVS's ROE is +0.28%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BVS is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BVS vs CATX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CATX has a market cap of 354.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CATX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CATX's P/E ratio is -2.34. In terms of profitability, BVS's ROE is +0.28%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BVS is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BVS vs TMCI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, TMCI has a market cap of 316.6M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while TMCI trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas TMCI's P/E ratio is -5.19. In terms of profitability, BVS's ROE is +0.28%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BVS is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BVS vs SMLR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BVS's ROE is +0.28%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BVS is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BVS vs TLSI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, TLSI has a market cap of 306.6M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while TLSI trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas TLSI's P/E ratio is -2.96. In terms of profitability, BVS's ROE is +0.28%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BVS is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
BVS vs CV Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, CV has a market cap of 298.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while CV trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas CV's P/E ratio is -2.39. In terms of profitability, BVS's ROE is +0.28%, compared to CV's ROE of -1.78%. Regarding short-term risk, BVS is similarly volatile compared to CV. This indicates similar risk in terms of short-term price fluctuations for BVS.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BVS vs RCEL Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, RCEL has a market cap of 271.8M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while RCEL trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas RCEL's P/E ratio is -7.60. In terms of profitability, BVS's ROE is +0.28%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BVS is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check RCEL's competition here
RxSight, Inc. (NASDAQ: RXST)
BVS vs RXST Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, RXST has a market cap of 270.7M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while RXST trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas RXST's P/E ratio is -5.79. In terms of profitability, BVS's ROE is +0.28%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BVS is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BVS.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
BVS vs PROF Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, PROF has a market cap of 247.1M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while PROF trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas PROF's P/E ratio is -6.94. In terms of profitability, BVS's ROE is +0.28%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BVS is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for BVS.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BVS vs INFU Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, INFU has a market cap of 245.4M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while INFU trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas INFU's P/E ratio is 29.66. In terms of profitability, BVS's ROE is +0.28%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BVS is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for BVS.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BVS vs MGRM Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BVS's ROE is +0.28%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BVS is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BVS.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
BVS vs ELMD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ELMD has a market cap of 228.4M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ELMD trades at $27.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ELMD's P/E ratio is 21.06. In terms of profitability, BVS's ROE is +0.28%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BVS is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
BVS vs NVRO Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BVS's ROE is +0.28%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BVS is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NVRO's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BVS vs BSGM Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BVS's ROE is +0.28%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BVS is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BSGM's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BVS vs STIM Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, STIM has a market cap of 189.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while STIM trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas STIM's P/E ratio is -6.18. In terms of profitability, BVS's ROE is +0.28%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BVS is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check STIM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BVS vs LUCD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, LUCD has a market cap of 181.5M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while LUCD trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas LUCD's P/E ratio is -2.57. In terms of profitability, BVS's ROE is +0.28%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BVS is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BVS vs MDGS Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BVS's ROE is +0.28%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BVS is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BVS vs QIPT Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BVS's ROE is +0.28%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BVS is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BVS vs FOCL Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while FOCL trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas FOCL's P/E ratio is -4.03. In terms of profitability, BVS's ROE is +0.28%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BVS is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for BVS.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BVS vs QSI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, QSI has a market cap of 153.1M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while QSI trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas QSI's P/E ratio is -1.68. In terms of profitability, BVS's ROE is +0.28%, compared to QSI's ROE of -0.47%. Regarding short-term risk, BVS is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for BVS.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
BVS vs INGN Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, INGN has a market cap of 147.6M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while INGN trades at $5.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas INGN's P/E ratio is -5.99. In terms of profitability, BVS's ROE is +0.28%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BVS is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BVS vs QTRX Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, QTRX has a market cap of 121.5M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while QTRX trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas QTRX's P/E ratio is -1.02. In terms of profitability, BVS's ROE is +0.28%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BVS is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
BVS vs ICAD Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BVS's ROE is +0.28%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BVS is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
BVS vs LNSR Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, LNSR has a market cap of 101.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while LNSR trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas LNSR's P/E ratio is 8.42. In terms of profitability, BVS's ROE is +0.28%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, BVS is more volatile compared to LNSR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BVS vs HJLI Comparison September 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 972.9M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BVS is priced at $14.23 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.89, whereas HJLI's P/E ratio is N/A. In terms of profitability, BVS's ROE is +0.28%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BVS is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check HJLI's competition here